Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

455 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer.
Sakai D, Chung HC, Oh DY, Park SH, Kadowaki S, Kim YH, Tsuji A, Komatsu Y, Kang YK, Uenaka K, Wijayawardana SR, Wacheck V, Wang X, Yamamura A, Doi T. Sakai D, et al. Among authors: kadowaki s. Cancer Chemother Pharmacol. 2017 Dec;80(6):1197-1207. doi: 10.1007/s00280-017-3445-z. Epub 2017 Oct 25. Cancer Chemother Pharmacol. 2017. PMID: 29071414 Free PMC article. Clinical Trial.
Impact of docetaxel in addition to cisplatin and fluorouracil as neoadjuvant treatment for resectable stage III or T3 esophageal cancer: a propensity score-matched analysis.
Nomura M, Oze I, Abe T, Komori A, Narita Y, Masuishi T, Taniguchi H, Kadowaki S, Ura T, Andoh M, Kawai R, Uemura N, Ishihara M, Tanaka T, Tajika M, Niwa Y, Muro K, Muto M. Nomura M, et al. Among authors: kadowaki s. Cancer Chemother Pharmacol. 2015 Aug;76(2):357-63. doi: 10.1007/s00280-015-2806-8. Epub 2015 Jun 20. Cancer Chemother Pharmacol. 2015. PMID: 26092324
Efficacy of Second-Line Bevacizumab-Containing Chemotherapy for Patients with Metastatic Colorectal Cancer following First-Line Treatment with an Anti-Epidermal Growth Factor Receptor Antibody.
Hasegawa H, Taniguchi H, Mitani S, Masuishi T, Komori A, Narita Y, Kadowaki S, Ura T, Ando M, Yatabe Y, Muro K. Hasegawa H, et al. Among authors: kadowaki s. Oncology. 2017;92(4):205-212. doi: 10.1159/000453336. Epub 2017 Feb 1. Oncology. 2017. PMID: 28142137 Clinical Trial.
Safety, pharmacokinetic, and clinical activity profiles of ramucirumab in combination with three platinum/fluoropyrimidine doublets in Japanese patients with chemotherapy-naïve metastatic gastric/gastroesophageal junction cancer.
Shitara K, Kadowaki S, Nishina T, Sakai D, Yoshikawa R, Piao Y, Ozeki A, Inoue K, Gritli I, Muro K. Shitara K, et al. Among authors: kadowaki s. Gastric Cancer. 2018 Jan;21(1):106-113. doi: 10.1007/s10120-017-0745-2. Epub 2017 Jun 30. Gastric Cancer. 2018. PMID: 28667466 Clinical Trial.
A Prospective Trial Evaluating the Safety of a Shortened Infusion of Ramucirumab in Patients with Gastrointestinal Cancer.
Hashimoto N, Mitani S, Taniguchi H, Narita Y, Kato K, Masuishi T, Kadowaki S, Onishi S, Tajika M, Takahashi S, Shimomura K, Takahata C, Hotta E, Kobara M, Muro K. Hashimoto N, et al. Among authors: kadowaki s. Oncologist. 2019 Feb;24(2):159-e66. doi: 10.1634/theoncologist.2018-0580. Epub 2018 Oct 10. Oncologist. 2019. PMID: 30305415 Free PMC article.
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study.
Shitara K, Iwata H, Takahashi S, Tamura K, Park H, Modi S, Tsurutani J, Kadowaki S, Yamaguchi K, Iwasa S, Saito K, Fujisaki Y, Sugihara M, Shahidi J, Doi T. Shitara K, et al. Among authors: kadowaki s. Lancet Oncol. 2019 Jun;20(6):827-836. doi: 10.1016/S1470-2045(19)30088-9. Epub 2019 Apr 29. Lancet Oncol. 2019. PMID: 31047804 Clinical Trial.
Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-naïve, HER2-positive advanced gastric cancer.
Takahari D, Chin K, Ishizuka N, Takashima A, Minashi K, Kadowaki S, Nishina T, Nakajima TE, Amagai K, Machida N, Goto M, Taku K, Wakatsuki T, Shoji H, Hironaka S, Boku N, Yamaguchi K. Takahari D, et al. Among authors: kadowaki s. Gastric Cancer. 2019 Nov;22(6):1238-1246. doi: 10.1007/s10120-019-00973-5. Epub 2019 May 17. Gastric Cancer. 2019. PMID: 31102009 Clinical Trial.
Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial.
Yoshikawa T, Muro K, Shitara K, Oh DY, Kang YK, Chung HC, Kudo T, Chin K, Kadowaki S, Hamamoto Y, Hironaka S, Yoshida K, Yen CJ, Omuro Y, Bai LY, Maeda K, Ozeki A, Yoshikawa R, Kitagawa Y. Yoshikawa T, et al. Among authors: kadowaki s. JAMA Netw Open. 2019 Aug 2;2(8):e198243. doi: 10.1001/jamanetworkopen.2019.8243. JAMA Netw Open. 2019. PMID: 31373648 Free PMC article. Clinical Trial.
455 results